Invesco Biotechnology & Genome ETF

Insightec Partners with Edison Science to Deploy Kosmos AI Platform for Accelerated Drug Development

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

InMed Pharmaceuticals

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

CN Energy

Generation Income Properties

MetaVia

Pinned News

置顶新闻

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

MAIR

RVMD

LABU

GraniteShares has filed with the SEC to launch three new 2x ETFs focused on high-volatility themes in nuclear energy, AI, and biotech. The ETFs aim to provide 200% daily performance of their underlying stocks: XE, MAIR, and RVMD. Designed for sophisticated investors and active traders, these products highlight a shift towards speculative investments as demand for high-beta trades increases.

benzinga_article

X-Energy

Madison Air Solutions

Revolution Medicines

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

NVIDIA

Tesla

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

NVIDIA Corporation

SVRA

SBIO

Savara's corporate presentation highlighted Phase 3 IMPALA-2 data for MOLBREEVI, showing significant improvement in DLCO% at Week 24 and sustained gains at Week 48 versus placebo. Patient-reported outcomes also improved at Week 24. The FDA BLA PDUFA date for MOLBREEVI is set for Nov. 22, 2026, with the drug still unapproved.

PUBT

Savara

ALPS Medical Breakthrough

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

SLXNW

SLXN

ARKG

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Unusual Whales

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Silexion Therapeutics

Ark Genomic Revolution ETF

iShares US Pharma

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

MEDP

Medpace Holdings shareholders approved charter amendments to remove supermajority voting requirements and limits on calling special meetings during the annual meeting on May 15, 2026. The changes will take effect on May 18, 2026. Additionally, shareholders owning at least 25% of voting power can now call special meetings, subject to certain conditions. A non-binding proposal for calling special meetings did not pass.

Medpace

Proshares Ultra Nasdaq Biotech

iShares Genomics Immunology and Healthcare ETF

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara presented 48-week data from the Phase 3 IMPALA-2 trial at the ATS International Conference 2026, showing long-term efficacy and safety of molgramostim in aPAP. Results indicated sustained lung function improvement and quality of life in patients on molgramostim, with those switching from placebo also showing benefits. The safety profile was consistent with previous trials, and 160 out of 164 enrolled patients completed the study, indicating strong retention.

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

nasdaq

Dyne Therapeutics

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

S&P 500

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

OCUL

Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1,504,880 shares for an estimated $14.34 million. The fund's reported assets fell by $18.27 million due to share sales and price changes. Ocular's recent performance has been mixed, with revenue growth lagging and net losses widening, despite positive clinical trial data. Investors are advised to consider other stocks, as Ocular was not included in a recent top investment list.

Ocular Therap

Netflix

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

ENVB

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.

Enveric Biosciences

IBBQ

BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion.

Beigene

VG Health

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

Sanofi reported 1.21 billion issued shares and 1.33 billion real voting rights as of April 30, 2026. Theoretical voting rights, including treasury shares, stood at 1.35 billion.

Sanofi

Sanofi reports 1.21 billion issued shares, 1.33 billion real voting rights as of April 30

Charles River Laboratories (CRL) shares have declined 18% in the past month, closing at $149.93, despite a 1-year total return of 6.05%. Analysts suggest the stock may be undervalued, with a fair value estimate of $313.61, while a DCF model indicates a lower value of $78.12. Investors are encouraged to weigh these differing perspectives and consider other investment opportunities in the healthcare sector.

Simplywall

Charles River Laboratorie

iShares US Healthcare Providers

Direxion S&P Biotech Bear 3X

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Eli Lilly

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Invesco Biotechnology & Genome ETF(PBE.US)

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP